Experience

FogPharma

• United States
• Biotechnology Research
• 100 - 200 Employee

• Scientist II

  • Jan 2022 - Present

  Cambridge, Massachusetts, United States Working in the Pharmaceutical Development group, responsible for developing scalable routes to APIs and developing and optimizing novel synthetic routes to access stapled peptides.



Syngenta

• Switzerland
• Farming
• 700 & Above Employee

• Technical Expert 2

  • Nov 2019 - Dec 2021

  Greensboro--Winston-Salem--High Point Area Working in the radiosynthesis group at Syngenta. Responsible for the synthesis of carbon-14 labelled compounds for metabolic studies, and for devising efficient synthetic routes to access radiolabelled compounds.



Princeton University

• United States
• Higher Education
• 700 & Above Employee

• Graduate Research Assistant

  • Aug 2014 - Oct 2019

  Graduate Research Assistant with Professor David W. C. MacMillan Frick Chemistry Laboratory, Princeton University, Princeton, NJ • Development of novel synthetic methodologies utilizing photoredox catalysis • Developed a method for the decarboxylative oxygenation of aliphatic carboxylic acids • Radicals formed via decarboxylation trapped by oxygen to form carbonyl products • Developed procedure for the synthesis of unnatural amino acids via metallaphotoredox-mediated… Show more Graduate Research Assistant with Professor David W. C. MacMillan Frick Chemistry Laboratory, Princeton University, Princeton, NJ • Development of novel synthetic methodologies utilizing photoredox catalysis • Developed a method for the decarboxylative oxygenation of aliphatic carboxylic acids • Radicals formed via decarboxylation trapped by oxygen to form carbonyl products • Developed procedure for the synthesis of unnatural amino acids via metallaphotoredox-mediated cross-electrophile coupling • Serine converted through its bromoalanine analogue to a range of unnatural phenylalanine and tryptophan products Show less



Evotec

• Germany
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Research Scientist

  • Aug 2013 - Jan 2014

  • Project sought to drug an oncology-relevant protein-protein interaction interface, in the lead to preclinical candidate phase of drug discovery • Involved the synthesis and purification of highly complex compounds, which contain multiple stereocenters, spirocycles and heterocyclic motifs